Hypoxic circumstances that inhibit the expression of cylindromatosis (CYLD), a tumor suppressor that acts as a deubiquitinating enzyme to control important signaling pathways, may be the cause of the decreased effectiveness of targeted treatments in the context of inflammation (65). This evidence concerns the gene CYLD and neoplasm.